MX387013B - Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2,4-oxadiazol-3-il)benzoico y procesos para su preparacion. - Google Patents

Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2,4-oxadiazol-3-il)benzoico y procesos para su preparacion.

Info

Publication number
MX387013B
MX387013B MX2018016250A MX2018016250A MX387013B MX 387013 B MX387013 B MX 387013B MX 2018016250 A MX2018016250 A MX 2018016250A MX 2018016250 A MX2018016250 A MX 2018016250A MX 387013 B MX387013 B MX 387013B
Authority
MX
Mexico
Prior art keywords
crystalline forms
rarî22
rarî2
dimethylbenzofuran
oxadiazol
Prior art date
Application number
MX2018016250A
Other languages
English (en)
Spanish (es)
Other versions
MX2018016250A (es
Inventor
Alan David Borthwick
Edwin Aret
Jane Theresa Brown
Jonathan Patrick Thomas Corcoran
Castro Vasconcelos Goncalves Maria Beatriz De
Ronnie Maxwell Lawrence
Sarkis Barret Kalindjian
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of MX2018016250A publication Critical patent/MX2018016250A/es
Publication of MX387013B publication Critical patent/MX387013B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2018016250A 2016-06-22 2017-06-16 Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2,4-oxadiazol-3-il)benzoico y procesos para su preparacion. MX387013B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610867.2A GB201610867D0 (en) 2016-06-22 2016-06-22 Crystalline forms of a therapeutic compound and processes for their preparation
PCT/EP2017/064802 WO2017220446A1 (en) 2016-06-22 2017-06-16 Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation

Publications (2)

Publication Number Publication Date
MX2018016250A MX2018016250A (es) 2019-08-29
MX387013B true MX387013B (es) 2025-03-19

Family

ID=56895172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016250A MX387013B (es) 2016-06-22 2017-06-16 Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2,4-oxadiazol-3-il)benzoico y procesos para su preparacion.

Country Status (10)

Country Link
US (2) US10870644B2 (OSRAM)
EP (1) EP3475274A1 (OSRAM)
JP (1) JP7102354B2 (OSRAM)
CN (1) CN109415356B (OSRAM)
AU (1) AU2017279865B2 (OSRAM)
CA (1) CA3025858C (OSRAM)
GB (1) GB201610867D0 (OSRAM)
IL (1) IL263786B (OSRAM)
MX (1) MX387013B (OSRAM)
WO (1) WO2017220446A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
CN111238897B (zh) * 2020-02-18 2023-03-28 上海市皮肤病医院 生物标本的处理方法与处理剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709475A (es) 1995-06-07 1998-02-28 Nippon Shinyaku Co Ltd Derivados de pirrol y composicion medicinal.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CN1211361C (zh) 1996-03-18 2005-07-20 卫材株式会社 含有稠环的羧酸衍生物
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US6355669B1 (en) 1997-10-22 2002-03-12 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
CA2449544A1 (en) * 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
WO2003062230A1 (en) 2002-01-21 2003-07-31 Eisai Co., Ltd. Conbinatorial library of heterocycle compounds
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
PL2910551T3 (pl) 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
MX2007004479A (es) 2004-10-13 2007-06-18 Ptc Therapeutics Inc Compuestoss para supresion sin sentido y metodos para su uso.
US20090176837A1 (en) 2005-07-12 2009-07-09 Sony Corporation Compounds with activity at retinoic acid receptors
EP2394647A1 (en) 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
EP2304366A2 (en) 2008-05-30 2011-04-06 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
EP3233842B1 (en) * 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation

Also Published As

Publication number Publication date
US20210230151A1 (en) 2021-07-29
CA3025858C (en) 2023-09-26
CN109415356A (zh) 2019-03-01
MX2018016250A (es) 2019-08-29
AU2017279865A1 (en) 2019-01-03
IL263786A (en) 2019-01-31
JP2019522650A (ja) 2019-08-15
AU2017279865B2 (en) 2020-11-26
WO2017220446A1 (en) 2017-12-28
US11584741B2 (en) 2023-02-21
GB201610867D0 (en) 2016-08-03
CA3025858A1 (en) 2017-12-28
IL263786B (en) 2022-05-01
JP7102354B2 (ja) 2022-07-19
US20190345147A1 (en) 2019-11-14
US10870644B2 (en) 2020-12-22
EP3475274A1 (en) 2019-05-01
CN109415356B (zh) 2022-03-08

Similar Documents

Publication Publication Date Title
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
IN2014DN03206A (OSRAM)
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
NZ598331A (en) Therapeutic aryl-amido-aryl compounds and their use
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
CA2894715C (en) Diazole amides
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MX387013B (es) Formas cristalinas del ácido 4-(5-(4,7-dimetilbenzofuran-2-il)-1,2,4-oxadiazol-3-il)benzoico y procesos para su preparacion.
UA117154C2 (uk) Антагоністи s1p3
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.